Drugging the MYOFIBROBLAST

A new approach to treating fibrosis

 
 
mediar_hero2_norounds.jpg

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.

The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.

Mediar’s foundational technology is based on pioneering research from Massachusetts General Hospital and Brigham and Women's Hospital.

The company was founded by Partners Innovation Fund in 2018
and is located at Lab Central, Cambridge’s premier biotechnology incubator.

color-background-area.jpg